SK Biopharmaceuticals Co., Ltd.
326030
Rank in Stocks
#4040
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Share Price
$51.65
Market Cap
$4.05B
Change (1 day)
0.27%
Change (1 year)
-30.95%
Country
KR
Trade SK Biopharmaceuticals Co., Ltd. (326030)
Category
Healthcare
Revenue for SK Biopharmaceuticals Co., Ltd. (326030)
Revenue in Jun 2026 TTM: $595.61M
According to SK Biopharmaceuticals Co., Ltd. latest financial reports the company's current revenue (TTM) is $595.61M. In 2024 the company made a revenue of $372.47M an increase over the revenue in the year 2023 that was $274.15M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for SK Biopharmaceuticals Co., Ltd. from 2011 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $595.61M | 21.75% |
| 2025 | $489.22M | 31.34% |
| 2024 | $372.47M | 35.86% |
| 2023 | $274.15M | 40.53% |
| 2022 | $195.08M | -44.60% |
| 2021 | $352.13M | 1,370.42% |
| 2020 | $23.95M | -77.67% |
| 2019 | $107.25M | 10,769.59% |
| 2018 | $986.74K | -98.77% |
| 2017 | $80.05M | 7.33% |
| 2016 | $74.58M | 22.73% |
| 2015 | $60.77M | -8.20% |
| 2014 | $66.20M | 15.28% |
| 2013 | $57.42M | 18.01% |
| 2012 | $48.66M | 49.86% |
| 2011 | $32.47M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 2,019.55% |
US
|
|
| $2.23B | 274.07% |
US
|
|
| $15.74B | 2,543.39% |
AU
|
|
| $6.02B | 910.94% |
NL
|
|
| - | - |
CH
|
